Global Advanced Visualization Market Analysis, Size, Share, Development and Forecast to 2023

According to the study, the global advanced visualization market is likely to grow from $1.8 billion in 2016 to $3.8 billion by 2023. Technological advancements, increasing demand for efficient and early diagnosis of diseases, and increasing prevalence of chronic diseases have been driving the growth of the global advanced visualization market. The market is further expected to gain revenue due to increasing geriatric population and incorporation of advanced visualization solutions in mobile devices. Integration of picture archiving and communication system (PACS) and advanced visualization solutions along with the rising demand from developing nations would create ample opportunities for the global advanced visualization vendors.

Explore Report Description at: https://www.psmarketresearch.com/market-analysis/advanced-visualization-market

As per the findings of research, hardware and software held larger share in the global market in 2016, primarily due to increasing installation of advanced visualization hardware and software in healthcare settings. The advanced visualization service market is expected to witness higher growth during the forecast period. The higher growth for services is attributed to the increasing demand for the implementation of advanced visualization solutions and training and education services. Among different type of advanced visualization solutions, enterprise-wide thin client-based solutions held larger share in the global market in 2016, and it is also expected to witness higher growth during the forecast period. Improved data storage capacity, multi-user interface, centralized post-processing solutions, streamlined analysis, and enhanced data transfer capabilities of these solutions is significantly driving the growth of the global enterprise-wide thin client-based solutions market.

Geographically, North America has been the largest market for advanced visualization, with the U.S. being the larger contributor to the regional market as compared to Canada. The key factor driving the North American advanced visualization market are technological advancements, increasing healthcare expenditure, growing geriatric population, improved healthcare infrastructure and growing prevalence of chronic diseases. According to the World Health Organization, approximately 324,000 new cases of lung cancer were diagnosed in North America in 2012, and the number is estimated to reach approximately 541,000 by 2030. The emerging economies in Asia-Pacific, especially China and India, are expected to grow tremendously in future, which is expected to bring the Asia-Pacific market approximately equal to the European market by 2023.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/advanced-visualization-market/report-sample

Key companies in the advanced visualization market are collaborating to offer better advanced visualization solutions. In November 2016, TeraRecon, released an advanced integration between iNtuition with Agfa HealthCare’s Enterprise Imaging 8.1. The combined solution provides single user interface for accessing 2D and advanced 3D applications, bi-directional communication between Agfa and TeraRecon viewers, and multi-series data loading for 3D analysis.

Some of the other key players in the market include General Electric Company, Canon, Inc., Siemens AG, Koninklijke Philips N.V, Fujifilm Holdings Corporation, Carestream Health, Agfa-Gevaert N.V., and Ziosoft.

ER+ Breast Cancer Pipeline Offers Novel Therapeutic Targets For The Treatment Of Breast Cancer

The study analyzed that the estrogen receptor positive breast cancer pipeline comprises approximately 74 drug candidates, of which nine products are in Phase III, 16 products in Phase II, 18 products in Phase I, and three products are in Pre-Clinical stage. The development of 14 ER+ breast cancer drug candidates was found to be inactive, and 14 products were discontinued. ER+ breast cancer is the most common type of breast cancer diagnosed and refers to the cancer cells that have receptors on their surface to bind with estrogen. Breast cancer is a syndrome that affects the breast tissues. In breast cancer, cells in the breast grow in an uncontrollable manner and form tumor, which can be felt as a lump or can be viewed under x-ray. Invasion of new therapeutic agents, such as gene therapy, cell therapy and monoclonal antibodies are expected to provide an effective and concrete treatment for the disease, more in the light of the new technologies available.

Access Report Overview: https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis

As per the findings of the research, a major share of ER+ breast cancer pipeline drug candidates are being developed to be administered by oral route and rest by intravenous route and subcutaneous route. Most of the therapeutic candidates are being developed to be administered by oral route due to high patient compliance.

Several companies are developing ER+ breast cancer drug candidates in different phases. Novartis AG, Syndax Pharmaceuticals, Tesaro, Inc. and others have their ER+ breast cancer drug candidates in Phase III stage of development. Novartis AG has three drug candidates in Phase III stage and two drug candidates in Phase I clinical stage.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis/report-sample

Some of the key players developing drugs for Estrogen Receptor-Positive (ER+) breast cancer are Chipscreen Biosciences, Ltd., Eli Lilly & Company, Genentech, Inc., Novartis AG, Ipsen, Syndax Pharmaceuticals, Inc., Tesaro, Inc Astellas Pharma Inc., AstraZeneca plc, and Bayer AG.

IgA Nephropathy Pipeline Analysis, 2017 - Clinical Trials & Results, Collaboration and Other Developments

The study analyzed that the IgA nephropathy pipeline comprises of 12 drug candidates, of which one drug candidate is in Phase III stage, five drug candidates are in Phase II stage and three drug candidates are in Pre-Clinical stage. Also, there are two inactive drug candidates and one discontinued drug candidate. IgA nephropathy, also known as Berger’s disease, is a kidney disorder that occurs when IgA antibody gets settled in the kidneys. This leads to inflammation that with time hinders the kidney’s ability to filter wastes from blood. IgA nephropathy is a silent disease in its early stages with no symptoms. But the most common symptoms that are usually observed are proteinuria and hematuria. IgA nephropathy does not have a specific treatment, and the only treatment available is to delay or prevent end stage renal disease (ESRD). Therefore, combination therapies are being used to slow down the rate of proteinuria and hematuria and the use of various targets including a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS) is expected to provide an effective and concrete treatment for the disease, with latest technological advancements further adding to the pipeline growth.

Browse the Report Summary at: https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis

As per the findings of the research, around 33.0% of drug candidates of IgA nephropathy pipeline are being developed to be administered by subcutaneous route and 22.0% are being developed to be administered by oral route. Route of administration of around 45.0% drug candidates of IgA nephropathy pipeline is not disclosed.

Many companies are involved in the development of IgA nephropathy pipeline, with their products in different phases. Mallinckrodt plc has its drug candidate in Phase III stage of development. Merck KGaA, Pharmalink AB, Anthera Pharmaceuticals, Inc., Rigel Pharmaceuticals, Inc. and Omeros Corporation each have their drug candidates in Phase II stage of development.

Browse Report Sample at: https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis/report-sample

Some of the key players developing drugs for IgA nephropathy include Mallinckrodt plc, Merck KGaA, Anthera Pharmaceuticals, Inc., Pharmalink AB, Rigel Pharmaceuticals, Inc., Omeros Corporation, IGAN Biosciences, Inc., Shire plc and Visterra, Inc.

Chronic Obstructive Pulmonary Disease Exhibits Emerging Pipeline with 60+ Drug Candidates

The study analyzed that the chronic obstructive pulmonary disease pipeline comprises 65 drug candidates, of which eight drug candidates are in Phase III stage of development, 24 drug candidates are in Phase II stage, nine drug candidates are in Phase I, 22 drug candidates are in Pre-Clinical stage and two drug candidates are in Discovery stage. Chronic obstructive pulmonary disease is a broad term used for progression of various other diseases that affect the lungs such as, emphysema, chronic bronchitis. In this condition, lung cells lose their elasticity and get enlarged, which leads to reduction in the amount of gas exchange in the lungs. Sometimes, it progresses to form cancer, stroke and coronary artery disease.

Explore Report at: https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis

As per the findings of the research, around 40.0% of the drug candidates of chronic obstructive pulmonary disease pipeline are being developed to be administered by inhalation route, 12.0% are being developed to be administered by oral route, 5.0% are being developed to be administered by subcutaneous route, 3.0% are being developed to be administered by intravenous route, 3.0% are being developed to be administered by another route and 37.0% are being developed to be administered by other routes that are undisclosed.

Many companies are involved in the development of drugs for the chronic obstructive pulmonary disease therapeutics pipeline, with their products in different phases. Chiesi Farmaceutici S.p.A., GlaxoSmithKline plc and AstraZeneca plc have their drug candidates in the Phase III stage of development. Adamis Pharmaceuticals Corporation has two drug candidates in Phase II stage of development. Novartis AG also has two drug candidates in Phase II stage of development. Glenmark Pharmaceuticals Ltd. has two drug candidates in Pre-Clinical stage of development.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis/report-sample

The research also found that various companies have collaborated for the development of chronic obstructive pulmonary disease therapeutics pipeline. In March 2017, Kyowa Hakko Kirin Co., Ltd. entered into an agreement with AstraZeneca plc for the exclusive rights of benralizumab for the treatment of severe asthma and chronic obstructive pulmonary disease in Asia. In June 2013, AstraZeneca plc acquired Pearl Therapeutics, Inc., which was involved in the development of inhaled small-molecule therapeutics for respiratory disease.

Some of the key players developing drugs for the treatment of chronic obstructive pulmonary disease include AstraZeneca plc, GlaxoSmithKline plc, Adamis Pharmaceuticals Corporation, Chiesi Farmaceutici S.p.A., Cytokinetics, Inc., Novartis AG and Theravance Biopharma R & D, Inc.

Oral Mucositis Exhibits Significant Growth in Pipeline with Maximum Drug Candidates in Phase II

The study analyzed that the oral mucositis therapeutics pipeline comprises approximately 18 drug candidates, of which one drug candidate is in Phase III stage of development, while seven drug candidates are in Phase II stage, four drug candidates are in Phase I stage, five drug candidates are in Pre-Clinical stage and one drug candidate is in the Discovery stage. Oral mucositis is the most common complication of chemotherapy in cancer patients. It causes damage to mucosal lining of the mouth which results in formation of ulcers. It can result in several problems that includes severe pain in mouth, nutritional problems as a result of inability to eat and increased risk of infection due to open sores in the mucosa.

Access Report Overview: https://www.psmarketresearch.com/market-analysis/oral-mucositis-therapeutics-pipeline-analysis

As per the findings of the research, around 39.0% drug candidates of oral mucositis pipeline are being developed to be administered by topical route, 17.0% are being developed to be administered by oral route, 17.0% are being developed to be administered by intravenous route and 5.0% by subcutaneous route. Route of administration of around 22.0% drug candidates of oral mucositis pipeline is not disclosed.

Many companies are involved in the development of drugs for the oral mucositis therapeutics pipeline, with their products in different phases. Daewoong Pharmaceutical Co., Ltd. has its drug candidates in the Phase III stage of development. Cellceutix Corporation, Onxeo S.A. and Novartis AG have their drug candidates in the Phase II stage of development. Galera Therapeutics, Inc. has two drug candidates each in Phase II and Phase I stage of development. Oragenics, Inc. has one drug candidate in Discovery stage of development.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/oral-mucositis-therapeutics-pipeline-analysis/report-sample

Some of the other key players developing drugs for the treatment of oral mucositis include Daewoong Pharmaceutical Co., Ltd., Cellceutix Corporation, Soligenix, Inc., Onxeo S.A., Novartis AG, TFS Corporation, Izun Pharmaceuticals Corp., Oragenics, Inc., Wellstat Therapeutics Corporation, Otsuka Holdings Co., Ltd. and Galera Therapeutics, Inc.

Contraceptives Market Size, Share, Development, Growth and Demand Forecast to 2023

The global contraceptives market is growing significantly due to increasing incidences of unwanted pregnancies, increasing prevalence of sexually transmitted diseases and advances in contraception techniques. In addition, government and non-government organizations are funding and supporting programs to encourage contraception. Large unexplored contraceptives market in emerging economies is creating ample opportunities for the global contraceptives market to grow at a considerable rate in the coming years. Several major players in the contraception market are actively involved in the research and new product development for contraception, which could meet the demand of cost effective long term contraception.

Explore Report at: https://www.psmarketresearch.com/market-analysis/contraceptives-market

Contraception is a method used to prevent pregnancy. Several contraceptives, such as hormonal drugs, physical barriers, and advanced contraceptive devices have been developed in order to prevent unwanted pregnancy. Contraceptives also help in preventing sexually transmitted infections. According to a report published by Guttmacher Institute, a non-profit organization working in advance sexual and reproductive health, 213.4 million pregnancies occurred across the globe in 2012, of which 40.0% were unintended. Also, high number of sexually transmitted infection is a major concern across the globe. According to the WHO, in 2013, 35.0 million people lived with HIV/AIDS and 1.5 million people died due to AIDS –related illness worldwide. The organization also reported that an estimated 500 million new curable sexually transmitted infections (including chlamydia, gonorrhoea, syphilis and trichomoniasis only) occur across the globe each year.

The global contraceptives market is categorized as devices and drugs. Based on devices, the contraceptives market is categorized as contraceptive sponges, vaginal rings, contraceptive diaphragms, intrauterine devices (IUDs), subdermal implants, male condoms, female condoms, and others. The IUDs segment is further categorized as hormonal IUDs and copper IUDs. On the basis of drugs, the contraceptive market can be categorized as topical contraceptives, contraceptive injectable, and contraceptive pills. Contraceptive pills lead the global contraceptive drugs market due to its convenience in use and high efficiency in emergency contraception.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/contraceptives-market/toc-sample

Some of the major players operating in the global Contraceptives market are CooperSurgical Inc., Mayer Laboratories Inc., Merck & Co. Inc., Bayer AG, Actavis Inc., Reckitt Benckiser plc, Pfizer Inc., The Female Health Company, Teva Pharmaceutical Industries Ltd.

Nerve Repair and Regeneration Market Size, Share, Development, Growth and Demand Forecast to 2023

According to the study, the global nerve repair and regeneration market is likely to grow significantly during the forecast period, due to increasing geriatric population, rising prevalence of chronic pain and increasing incidence of neurological disorders. In addition, the awareness about mental diseases and their treatment and technological advancement in nerve repair and regeneration products is also increasing globally, which contributes to the growth of the market. Lack of skilled professionals, high cost and side effects associated with the usage of neurostimulation and neuromodulation devices are the key factors restraining the global market growth.

Access Report Overview: https://www.psmarketresearch.com/market-analysis/nerve-repair-and-regeneration-market

Insights on market segments

As per the findings of the research, the market for neurostimulation and neuromodulation devices was larger than the market for biomaterials. Internal devices form the larger part of the global neurostimulation and neuromodulation devices market. Within internal neurostimulation and neuromodulation devices, spinal cord stimulation devices generate the largest revenue in the global market. Based on application, neurostimulation and neuromodulation surgeries has been the largest application area of the global nerve repair and regeneration market, followed by direct nerve repair/neurorrhaphy, nerve grafting and stem cell therapy.

North America stands as the largest nerve repair and regeneration market

Geographically, North America has been the largest market for nerve repair and regeneration, with the U.S. being the largest contributor to the regional market. Increasing incidence of peripheral nerve injuries and presence of technological advanced products has been driving the growth of the North American market. In Europe, Germany has been the largest contributor to the nerve repair and regeneration market, followed by the U.K. and France. The market is expected to witness highest growth in Asia-Pacific, during 2017 - 2023, owing to increasing cases of neurological disorders and increasing geriatric population.

Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/nerve-repair-and-regeneration-market/report-sample

Key players in the nerve repair and regeneration market

Some of the key players in the global nerve repair and regeneration market include Boston Scientific Corporation, Axogen, Inc., Cyberonics, Inc., Medtronic, PLC, Baxter International Inc., St. Jude Medical, Inc., Integra Lifesciences Holdings Corporation, Inc., Stryker Corporation, Orthomed S.A.S. and Polyganics B.V.

Oligonucleotide Synthesis Market Trends, Size, Development and Demand Forecast to 2023

According to the study, the global oligonucleotide synthesis market is likely to grow from $1.3 billion in 2016 to $2.7 billion by 2023. Recent technological and other advances, leading to cost effective and rapid synthesis of oligomers, increased government funding and other initiatives, have been driving the global oligonucleotide synthesis market. The market is further expected to gain revenue from increased focus on personalized medicine, offering tailored medical treatment to individual characteristics, needs and preferences of patients and rising compliance for oligonucleotide synthesis in the emerging economies.

Browse the Report Summary at: https://www.psmarketresearch.com/market-analysis/oligonucleotide-synthesis-market

Insights on market segments

As per the findings of research, globally synthesized oligonucleotide is the largest product of oligonucleotide synthesis market, followed by reagents and equipment. Based on application, synthesized oligonucleotide finds largest application in research, followed by diagnostic and therapeutic.

North America stands as the largest oligonucleotide synthesis market

Geographically, North America has been the largest market for oligonucleotide synthesis market, with the U.S. being the largest contributor to the regional market. In Europe, the U.K. has been the largest region contributing to oligonucleotide synthesis market, followed by Germany and France.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/oligonucleotide-synthesis-market/report-sample

Key players in the oligonucleotide synthesis market actively seeking acquisitions

The oligonucleotide synthesis market has witnessed number of mergers and acquisitions and strategic alliances recently. The companies are actively seeking acquisitions to broaden their portfolio of life sciences products. In 2015, Merck completed the acquisition of Sigma-Aldrich Co. LLC that manufactures biochemical, organic chemical products, kits and services. In December 2016, Ajinomoto Co. Inc. announced the acquisition of GeneDesign, Inc. to tap the growing demand of CDMOs for nucleic acid drugs in the Japanese market. In December 2015, Integrated DNA Technologies Inc. announced acquisition of the oligonucleotide synthesis business of AITbiotech Pte. Ltd., based in Singapore. The company aims to widen its customer base in the Southeast Asian market through this acquisition.

The major players including GE healthcare, Thermo Fisher Scientific Inc., Integrated DNA Technologies, Inc., Trilink Biotechnologies LLC, Eurogentec S.A., and Merck KGaA offer products across all the segments of the market. Some of the other key players in the market include LGC Biosearch Technologies, Inc., Bioautomation Corporation, Integrated DNA Technologies, Inc., GeneDesign, Inc., Trilink Biotechnologies LLC, Merck KGaA, Eurofins Scientific SE, Thermo Fisher Scientific Inc., General Electric Company and Eurogentec S.A.